Correlation Between Karyopharm Therapeutics and Allogene Therapeutics

Can any of the company-specific risk be diversified away by investing in both Karyopharm Therapeutics and Allogene Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Karyopharm Therapeutics and Allogene Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Karyopharm Therapeutics and Allogene Therapeutics, you can compare the effects of market volatilities on Karyopharm Therapeutics and Allogene Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Karyopharm Therapeutics with a short position of Allogene Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Karyopharm Therapeutics and Allogene Therapeutics.

Diversification Opportunities for Karyopharm Therapeutics and Allogene Therapeutics

0.16

Correlation Coefficient

Karyopharm Therapeutics  Allogene Therapeutics

Average diversification

The 3 months correlation between Karyopharm and Allogene is 0.16. Overlapping area represents the amount of risk that can be diversified away by holding Karyopharm Therapeutics and Allogene Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Allogene Therapeutics and Karyopharm Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Karyopharm Therapeutics are associated (or correlated) with Allogene Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Allogene Therapeutics has no effect on the direction of Karyopharm Therapeutics i.e., Karyopharm Therapeutics and Allogene Therapeutics go up and down completely randomly.

Pair Corralation between Karyopharm Therapeutics and Allogene Therapeutics

Given the investment horizon of 90 days Karyopharm Therapeutics is expected to under-perform the Allogene Therapeutics. But the stock apears to be less risky and, when comparing its historical volatility, Karyopharm Therapeutics is 1.14 times less risky than Allogene Therapeutics. The stock trades about 0.0 of its potential returns per unit of risk. The Allogene Therapeutics is currently generating about 0.03 of returns per unit of risk over similar time horizon. If you would invest  244.00  in Allogene Therapeutics on September 3, 2024 and sell it today you would earn a total of  4.00  from holding Allogene Therapeutics or generate 1.64% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Karyopharm Therapeutics  vs.  Allogene Therapeutics

Karyopharm Therapeutics

Risk-Adjusted Performance

5 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Karyopharm Therapeutics are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite fairly weak basic indicators, Karyopharm Therapeutics demonstrated solid returns over the last few months and may actually be approaching a breakup point.

Allogene Therapeutics

Risk-Adjusted Performance

1 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Allogene Therapeutics are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of very weak essential indicators, Allogene Therapeutics may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Pair Trading with Karyopharm Therapeutics and Allogene Therapeutics

The main advantage of trading using opposite Karyopharm Therapeutics and Allogene Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Karyopharm Therapeutics position performs unexpectedly, Allogene Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allogene Therapeutics will offset losses from the drop in Allogene Therapeutics' long position.

The idea behind Karyopharm Therapeutics and Allogene Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.